Meeting Banner
Abstract #1131

A fluorine-19 MR characterization of ABL-101 - a novel tracer with high biocompatibility and MR sensitivity

Emeline Darçot1, Roberto Colotti1, David Brennan2,3, Graeme A Deuchar3, Celestine Santosh2,3, and Ruud B van Heeswijk1,4

1Radiology, Lausanne University Hospital (CHUV), Lausanne, Switzerland, 2Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow, United Kingdom, 3Aurum Biosciences Ltd, Glasgow, United Kingdom, 4Center for BioMedical Imaging (CIBM), Lausanne and Geneva, Switzerland

A major challenge that slows down the translation of fluorine-19 (19F) MRI for inflammation monitoring and cell tracking into clinical practice is the need for perfluorocarbons (PFCs) that have good biocompatibility while also being suitable for 19F MRI. We therefore characterized ABL-101, a perfluoro(t-butylcyclohexane) emulsion, as a 19F MRI tracer. ABL-101 had T2/T1 ratios and detection limits similar to PFCs developed specifically for MRI. This combined with the short clearance half-life of this intravenous emulsion make ABL-101 a very promising candidate as a tracer in future clinical trials that use 19F MRI.

This abstract and the presentation materials are available to members only; a login is required.

Join Here